Israel’s NeuroDerm has released positive preliminary results for the final Phase II trial of its ND0612H treatment on 38 patients with advanced Parkinson’s disease.  NeuroDerm will now proceed with Phase III trials on 240 patients prior to requesting CE (European) Certification.

http://ir.neuroderm.com/phoenix.zhtml?c=253749&p=irol-newsArticle&ID=2250523